Enanta/$ENTA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Enanta
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.
Ticker
$ENTA
Sector
Primary listing
Employees
120
Headquarters
Website
Enanta Metrics
BasicAdvanced
$422m
-
-$2.47
1.01
-
Price and volume
Market cap
$422m
Beta
1.01
52-week high
$17.15
52-week low
$5.03
Average daily volume
153k
Financial strength
Current ratio
3.842
Quick ratio
3.695
Long term debt to equity
129.858
Total debt to equity
160.067
Interest coverage (TTM)
-5.80%
Profitability
EBITDA (TTM)
-55.43
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-89.56%
Operating margin (TTM)
-87.24%
Effective tax rate (TTM)
-0.15%
Revenue per employee (TTM)
$580,000
Management effectiveness
Return on assets (TTM)
-11.84%
Return on equity (TTM)
-59.00%
Valuation
Price to revenue (TTM)
5.277
Price to book
3.62
Price to tangible book (TTM)
3.62
Growth
Revenue change (TTM)
7.37%
Earnings per share change (TTM)
-45.58%
3-year revenue growth (CAGR)
-5.18%
10-year revenue growth (CAGR)
-2.31%
3-year earnings per share growth (CAGR)
-25.58%
10-year earnings per share growth (CAGR)
3.80%
What the Analysts think about Enanta
Analyst ratings (Buy, Hold, Sell) for Enanta stock.
Enanta Financial Performance
Revenues and expenses
Enanta Earnings Performance
Company profitability
Enanta News
AllArticlesVideos
Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026
Business Wire·1 week ago
Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026
Business Wire·1 month ago
Enanta Pharmaceuticals to Present at The Citizens Life Sciences Conference
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Enanta stock?
Enanta (ENTA) has a market cap of $422M as of May 13, 2026.
What is the P/E ratio for Enanta stock?
The price to earnings (P/E) ratio for Enanta (ENTA) stock is 0 as of May 13, 2026.
Does Enanta stock pay dividends?
No, Enanta (ENTA) stock does not pay dividends to its shareholders as of May 13, 2026.
When is the next Enanta dividend payment date?
Enanta (ENTA) stock does not pay dividends to its shareholders.
What is the beta indicator for Enanta?
Enanta (ENTA) has a beta rating of 1.01. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.